BioSpace News Archive

Health Canada is investigating the risk of serious heart-related issues and cancer with the use of Xeljanz and Xeljanz XR (tofacitinib).

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 20 th Annual Needham Virtual Healthcare Conference on Tuesday, April 13 th at 2:15 P.M. ET.

Atreca, Inc., a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced that it will participate in the following upcoming virtual investor conferences:

BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on April 5, 2021, the compensation committee of BridgeBio’s board of directors granted 19 new employees restricted stock units for an aggregate of 32,691 shares of the Company’s common stock.

NANO-X IMAGING LTD, the innovative medical imaging technology company democratizing healthcare, announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission on April 6, 2021.

Clean Tec Services, the central Florida-based commercial and hospitality maintenance management and cleaning specialist, has partnered with BioAssured to bring the BioAssured Certification to their extensive hotel client base.

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD).

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the commencement of a proposed underwritten public offering of 2,500,000 shares of its common stock by Outset and 2,500,000 shares of its common stock by certain of its stockholders.

TestDirectly connects medical labs with school districts for comprehensive and easy to implement COVID-19 testing solutions.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A